Welcome to our dedicated page for Aura Biosciences news (Ticker: AURA), a resource for investors and traders seeking the latest updates and insights on Aura Biosciences stock.
Aura Biosciences, Inc. (NASDAQ: AURA) is a clinical-stage biotechnology company headquartered in Boston, Massachusetts, developing precision therapies for solid tumors that aim to preserve organ function. News about AURA stock frequently centers on clinical trial milestones, regulatory designations, financing activities, and participation in healthcare and investor conferences.
A key theme in Aura’s news flow is progress with its lead candidate, bel-sar (AU-011). The company regularly reports updates on the global Phase 3 CoMpass trial in early or early-stage choroidal melanoma, which it describes as the first registration-enabling study in this indication. Press releases also cover developments in additional ocular oncology programs, including metastases to the choroid and cancers of the ocular surface, and in non-muscle invasive bladder cancer, where Aura has shared Phase 1 data and details of an ongoing Phase 1b/2 trial.
Investors following AURA news can expect recurring coverage of regulatory interactions, such as Orphan Drug and Fast Track designations for bel-sar, as well as financial updates through quarterly and annual results furnished via Form 8-K. Aura’s announcements also include public offering details, cash runway commentary, and information about patent applications for new formulations of bel-sar in urologic oncology.
In addition, Aura frequently announces participation in healthcare and life sciences conferences, fireside chats, and investor events, where senior management discusses the company’s pipeline and strategy. For anyone tracking AURA, this news page provides a centralized view of Aura Biosciences’ clinical progress, corporate developments, and capital markets activity over time.
Aura Biosciences Inc. (NASDAQ: AURA) announced significant clinical milestones for AU-011 in oncology, including the initiation of pivotal trials in choroidal melanoma and phase 1 trials for non-muscle invasive bladder cancer. The company reported Q1 2022 financials, showing a net loss of $12.8 million, up from $5.9 million in Q1 2021. Operating expenses rose due to increased R&D and administrative costs. As of March 31, 2022, Aura had $133.3 million in cash, sufficient to fund operations into 2024. The company maintains a focus on developing VDC therapies for various cancer indications.
Aura Biosciences (NASDAQ: AURA) presented new preclinical data for its VDC product candidate, AU-011, at the ARVO Annual Meeting in Denver. The data indicates AU-011's targeted cytotoxicity against tumor cells commonly metastasizing to the choroid, including breast, renal, and colon cancers. CEO Elisabet de los Pinos emphasized the potential of AU-011 as a treatment for ocular cancers. The company plans to submit an IND for choroidal metastasis in the latter half of this year, further advancing its ocular oncology initiatives.
Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology firm, announces that CEO Elisabet de los Pinos will present at the 2022 Bank of America Healthcare Conference in Las Vegas on May 10, 2022, at 4:55 p.m. PT. The presentation will be available via a live webcast on Aura's website, with a replay accessible for 90 days thereafter.
Aura specializes in virus-like drug conjugate therapies for oncology, with its lead candidate, AU-011, targeting ocular cancers, specifically choroidal melanoma. The company aims to broaden the use of AU-011 in multiple cancers, including bladder cancer.
Aura Biosciences reported its financial results for the fourth quarter and year ending December 31, 2021, highlighting advancements in its AU-011 program. The company is set to initiate pivotal trials for early-stage choroidal melanoma and a Phase 1 trial for non-muscle invasive bladder cancer in the second half of 2022. Aura received Orphan Drug Designation from the European Commission for AU-011, enhancing its market position. The cash position of $149.1 million is expected to fund operations into 2024, despite increased R&D expenses resulting in a net loss of $35.3 million for the year.
Aura Biosciences Inc. (NASDAQ: AURA) has received Orphan Drug Designation from the European Commission for its first virus-like drug conjugate (VDC) candidate, AU-011, aimed at treating uveal melanoma, including choroidal melanoma. Choroidal melanoma represents 90% of uveal melanomas and currently lacks approved therapies for early stages. This designation highlights the urgent need for treatment options. AU-011 is now in Phase 2 clinical trials and is expected to expand into choroidal metastasis. The company is aligned with U.S. and European agencies for its pivotal programs.
Aura Biosciences Inc. (NASDAQ: AURA) will host a virtual Investor Day on March 22, 2022, from 11:00 a.m. to 12:30 p.m. ET. The event will feature presentations by notable ocular oncology experts, Dr. Carol Shields and Dr. Hans Grossniklaus, focusing on choroidal melanoma and the novel therapy AU-011. The company plans to finalize the treatment regimen for AU-011 and initiate a pivotal program in the latter half of 2022. The event can be accessed via phone or through a live webcast on Aura's investor website.
Aura Biosciences Inc. (NASDAQ: AURA) presented preclinical data for its first Virus-Like Drug Conjugate (VDC) candidate, AU-011, at the 2022 American Association for Cancer Research Annual Meeting. Targeting aggressive cancers like primary choroidal melanoma and non-muscle invasive bladder cancer, results indicate AU-011's potential effectiveness across multiple solid tumor types. The findings enhance understanding of tumor cell biology and signal opportunities for expanding clinical trials. The company is focused on developing AU-011 for ocular and potentially broader oncological applications.
Aura Biosciences Inc. (NASDAQ: AURA), a biotechnology firm focused on innovative virus-like drug conjugate (VDC) therapies for cancer, announced CEO Elisabet de los Pinos will join a panel discussion on “Auditory and Ophthalmology” at the 42nd Annual Cowen Virtual Health Care conference on March 7, 2022, at 2:10 p.m. ET. A live webcast will be available on the company’s website, with a replay archived for 90 days. Aura’s lead candidate, AU-011, targets ocular cancers and is undergoing a Phase 2 clinical trial for choroidal melanoma, a severe eye cancer.
Aura Biosciences (NASDAQ: AURA) announced its upcoming Phase 1 clinical trial for AU-011, a virus-like drug conjugate targeting Non-Muscle Invasive Bladder Cancer (NMIBC). This follows the presentation of promising preclinical data at the 2022 ASCO Genitourinary Cancer Symposium. AU-011 shows consistent tumor cell binding and cytotoxicity, indicating its potential efficacy across all tumor grades. The trial is set to begin in the second half of 2022, focusing on addressing the unmet need for effective treatments in NMIBC.
Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology firm, will have CEO Elisabet de los Pinos participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference on February 16, 2022, at 8:40 a.m. ET. The discussion will be accessible via a live webcast on the company's Investors & Media page, with a replay available for 90 days. Aura is focusing on developing its lead therapy AU-011 for ocular cancers, including a Phase 2 trial for choroidal melanoma.